Articles | November 23, 2020
ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. Read More
Mission | November 16, 2020
Depression is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide, affecting an estimated 300 million people globally. Approximately one third of patients with major depressive disorder are diagnosed with treatment resistant depression. Symptoms vary, but generally, clinical depression is characterized by: Persistent… Read More
Mission | November 16, 2020
Substance Use Disorders (SUDs) and related disorders are a significant source of morbidity and mortality and pose a substantial cost to society Over 20m people live with a SUD in the U.S., and since the drug epidemic started in 1999, there have been over 900,000 overdose fatalities. For an already vulnerable population, COVID-19 severely exacerbated… Read More
Mission | November 16, 2020
Anxiety is considered a common aspect of life, however anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time. Anxiety disorders, which are believed to stem from a set of risk factors including genetics, neurochemistry, life experiences and personality, can have… Read More
News | November 9, 2020
Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in psychedelic medicine at the 2019 Mapping the Mind conference in Toronto. The conference, which featured speakers like Dr. David Nichols, founding president of the Heffter Insitute, and Dr. Matthew Johnson, associate director… Read More
Articles | November 8, 2020
We’re social creatures: We not only desire interaction with others but actually need it. Contact with others… Read More
Articles | November 8, 2020
Gender greatly influences the power that males and females have over socio-economic factors that influence their mental health, social position… Read More
Articles | October 27, 2020
ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has… Read More
Articles | October 9, 2020
Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. Painful both mentally and physically,… Read More
Articles | August 25, 2020
For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with PTSD. Rick Doblin, for years psychedelic therapy’s most prominent advocate and fundraiser, and his non-profit, MAPS, have raised millions to advance clinical trials, most recently… Read More
JOIN THE ATAI #INSIGHTNETWORK